Celldex Therapeutics, Inc. (CLDX): Total Liabilities
$55.82M
As of 2025-12-31
$67.78M
As of 2026-06-30
+28.1%
3-year compound annual growth
+16.1%
5-year compound annual growth
+1.6%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $55.82M | +23.1% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $45.34M | +24.4% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $36.46M | +37.4% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $26.53M | +5.4% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $25.18M | -4.9% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $26.48M | -8.4% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $28.91M | -9.0% | 2021-03-29, Balance as of period end |
| 2018-12-31 | $31.75M | -59.9% | 2020-03-26, Balance as of period end |
| 2017-12-31 | $79.25M | -32.8% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $117.93M | +148.4% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $47.48M | +30.6% | 2017-03-14, Balance as of period end |
| 2014-12-31 | $36.35M | +33.2% | 2016-02-25, Balance as of period end |
| 2013-12-31 | $27.30M | -8.3% | 2015-02-24, Balance as of period end |
| 2012-12-31 | $29.77M | +1.7% | 2014-03-03, Balance as of period end |
| 2011-12-31 | $29.27M | -15.6% | 2013-03-08, Balance as of period end |
| 2010-12-31 | $34.69M | n/a | 2012-03-08, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $55.82M | +23.1% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $42.49M | +19.7% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $57.22M | +20.8% |
| Biomerica Inc (BMRA) | 2026-05-31 | $4.13M | +124.4% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $87.8K | -94.9% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $12.39M | +53.8% |
| Immucell Corp (ICCC) | 2025-12-31 | $15.48M | -12.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $34.81M | -4.3% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $170.73M | -46.5% |
Compare CLDX, VNRX, IMDX, BMRA side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗